Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease

Patients with multiple myeloma, an incurable malignancy of plasma cells, frequently develop osteolytic bone lesions that severely impact quality of life and clinical outcomes. Eliglustat, a U.S. Food and Drug Administration-approved glucosylceramide synthase inhibitor, reduced osteoclast-driven bone...

Full description

Bibliographic Details
Main Authors:	Leng, H, Zhang, H, Li, L, Zhang, S, Wang, Y, Chavda, SJ, Galas-Filipowicz, D, Lou, H, Ersek, A, Morris, EV, Sezgin, E, Lee, Y-H, Li, Y, Lechuga-Vieco, AV, Tian, M, Mi, J-Q, Yong, K, Zhong, Q, Edwards, CM, Simon, AK, Horwood, NJ
Format:	Journal article
Language:	English
Published:	Springer Nature 2022

Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease

Similar Items